Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer

Lung Cancer

Volumn 34, Issue 2, 2001, Pages 261-269

  Novello, Silvia ^a   Galli, Luca ^b   Antonuzzo, Andrea ^b   Crinó, Lucio ^c   Pozzi, Ernesto ^a   Selvaggi, Giovanni ^a   Ricci, Sergio ^b   Marrocolo, Francesca ^c   Darwish, Samir ^d   Sorbolini, Sara ^d   Tonato, Maurizio ^d   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c BELLARIA HOSPITAL   (Italy)

^d Policlinico Hospital   (Italy)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; COLONY STIMULATING FACTOR; DEXAMETHASONE; GRANISETRON; ONDANSETRON; ORPHENADRINE; PACLITAXEL; PREDNISONE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034771269     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00238-0     Document Type: Article

References (32)

1. Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patient from 52 randomized clinical trials
2. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non small cell lung cancer. A meta-analysis
3. Long-term survivors in metastatic non small cell lung cancer: An Eastern Cooperative Group study
4. Combination chemotherapy versus single agent followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
5. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861
6. Randomized Pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer
7. Novel chemotherapeutic agents in the treatment of non small cell lung cancer
8. Phase I and pharmacologic study of paclitaxel and cisplatin with G-CSF: Neuromuscular toxicity is dose-limiting
9. Phase I/II dose finding study of paclitaxel and carboplatin in advanced non small cell lung cancer
10. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
11. Nonparametric estimation from incomplete observation
12. A phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results
13. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer
14. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small cell lung cancer
15. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer
16. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer
17. Comparison of survival and quality of life in advanced treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
18. Cisplatin/paclitaxel vs. cisplatin/teniposide for advanced non-small cell lung cancer
19. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response and survival analysis
20. New drugs for new chemotherapy standards
21. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations
22. 2) plus carboplatin (AUC6) in advanced non small cell lung cancer
23. Randomized phase II trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced non small cell lung cancer (NSCLC)
24. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated non small cell lung cancer (NSCLC)
25. Extensive and saturable accumulation of paclitaxel by the human platelet
26. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
27. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy
28. A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer
29. E-1594 - A randomised phase III trial in metastatic non-small cell lung cancer. Outcome of PS 2 patients: An Eastern cooperative group trial
30. A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: A phase II randomized trial
31. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung. A randomised phase III study of the Italian Lung Cancer Project